Enzo Biochem Stock Today
| ENZ Stock | USD 1.14 0.01 0.88% |
Performance6 of 100
| Odds Of DistressLess than 26
|
Enzo Biochem is trading at 1.14 as of the 5th of October 2024; that is 0.88 percent increase since the beginning of the trading day. The stock's open price was 1.13. Enzo Biochem has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Enzo Biochem are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of August 2024 and ending today, the 5th of October 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 12th of June 1980 | Category Healthcare | Classification Health Care |
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is headquartered in Farmingdale, New York. The company has 51.46 M outstanding shares of which 478.73 K shares are currently shorted by investors with about 8.01 days to cover. More on Enzo Biochem
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Enzo Stock Highlights
| CEO | Hamid Erfanian | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [ENEL GREEN POWER , ENEL GREEN POWER - Dusseldorf Stock Exchang, ENEL GREEN POWER (ENZ.SG), Enzumo Limited] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, NYSE Composite, Healthcare, Health Care, Health Care Providers & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEnzo Biochem can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enzo Biochem's financial leverage. It provides some insight into what part of Enzo Biochem's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Enzo Biochem (ENZ) is traded on New York Stock Exchange in USA. It is located in 81 Executive Blvd., Farmingdale, NY, United States, 11735 and employs 179 people. Enzo Biochem is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 58.66 M. Enzo Biochem runs under Health Care Providers & Services sector within Health Care industry. The entity has 51.46 M outstanding shares of which 478.73 K shares are currently shorted by investors with about 8.01 days to cover.
Enzo Biochem has about 82.37 M in cash with (36.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Enzo Biochem Probability Of Bankruptcy
Ownership AllocationEnzo Biochem holds a total of 51.46 Million outstanding shares. Enzo Biochem retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Enzo Ownership Details
Enzo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 71.8 K | |
| Northern Trust Corp | 2024-06-30 | 67.2 K | |
| Lazard Asset Management Llc | 2024-06-30 | 50.5 K | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 44.8 K | |
| Xtx Topco Ltd | 2024-06-30 | 28.3 K | |
| Kempner Capital Management Inc | 2024-06-30 | 25.5 K | |
| Assenagon Asset Management Sa | 2024-06-30 | 19.8 K | |
| Millennium Management Llc | 2024-06-30 | 19.4 K | |
| Raymond James Trust Co | 2024-06-30 | 17 K | |
| Harbert Fund Advisors Inc | 2024-06-30 | 5.2 M | |
| Renaissance Technologies Corp | 2024-06-30 | 2.5 M |
Enzo Biochem Historical Income Statement
Enzo Stock Against Markets
Enzo Biochem Corporate Directors
| Mary Tagliaferri | Lead Independent Director | Profile | |
| Dov Perlysky | Lead Independent Director | Profile | |
| Ian Walters | Independent Director | Profile | |
| Bruce Hanna | Independent Director | Profile |
Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.